Last reviewed · How we verify
Oxycodone - Part B
At a glance
| Generic name | Oxycodone - Part B |
|---|---|
| Sponsor | Indivior Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Abuse Potential of Intranasal Cebranopadol (PHASE1)
- Buprenorphine-Fentanyl Interaction Study (PHASE1)
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
- A Safety, Tolerability, PD and PK Study in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycodone - Part B CI brief — competitive landscape report
- Oxycodone - Part B updates RSS · CI watch RSS
- Indivior Inc. portfolio CI